Reports

11655 Results (Page 240 of 467)

All Market Research Reports

Rare Diseases

France Fibrodysplasia Ossificans Progressiva Drugs Market Analysis

France Fibrodysplasia Ossificans Progressiva Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for Fibrodysplasia Ossificans Progressiva Drugs is expanding as a result of growing incidence and prevalence of fibrodysplasia ossificans progressiva , increase in the number of R&D activities, increase in Partnerships and Collaborations between market players. Pfizer Inc., AstraZeneca, Limited, Regeneron Pharmaceuticals, Inc, Clementia Pharmaceuticals, Novartis are the top key market players operating in the global Fibrodysplasia Ossificans Progressiva Drugs market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Spain Rett Syndrome Drugs Market Analysis

Spain Rett Syndrome Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for Rett syndrome will grow over time as a result of expanding female population, rising public healthcare programme spending for patient advocacy and rising global healthcare expenditure. Major global players in Rett Syndrome Drugs Market are Merck KGaA (Germany), Eisai Co., Ltd. (Japan), AstraZeneca (U.K.), Sanofi (France), Novartis AG (Switzerland), Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Teva Pharmaceutical Industries Ltd. (Ireland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), WOCKHARDT (Mumbai), Novo Nordisk A/S (Denmark), Glenmark Pharmaceuticals Limited (India), Cipla Inc. (U.S.), Bausch Health Companies Inc. (Canada), Otsuka America Pharmaceutical, Inc. (U.S.), Johnson & Johnson Private Limited (U.S.), Takeda Pharmaceutical Company Limited (Japan), Sumitomo Corporation (Japan), Biocon (India)

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Japan Fabry Disease Therapeutics Market Analysis

Japan Fabry disease Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. A lack of lysosomal hydrolase -galactosidase causes Fabry disease (FD), an X-linked inborn error of lysosomal storage disorder. A activity brought on by harmful variations in the GLA gene. The market for fabry disease drugs is growing rapidly as a result of increase in incidence and prevalence of fabry disease globally, increase in awareness about the disease globally, better diagnosis rates, improved access to treatment, development of new emerging therapies, orphan drug designations provided by regulatory bodies, increase in stratergic collaborations, rise in research and development activities and approval of promising pipeline products. Chiesi Farmaceutici SpA, Sanofi, Shire, Takeda Pharmaceutical Company Limited, Amicus Therapeutics, Inc., JCR Pharmaceuticals, Moderna are the key market players operating in global fabry disease Therapeutics Market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Brazil Myasthenia Gravis Therapeutics Market Analysis

Brazil myasthenia gravis therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The myasthenia gravis market engages in all of these activities, including regulatory approvals, the introduction of new products, the purchase of other companies, and joint ventures with them. These strategies will definitely contribute to the growth of the global industry. Major global players in this market are Alexion Pharmaceuticals, Inc., Bausch Health Companies, Inc., Novartis AG, Amneal Pharmaceuticals LLC, Zydus Cadila, Avadel, Dr. Reddy's Laboratories, Ltd., Fresenius Kabi, AG, Endo Pharmaceuticals, Inc., Amphastar Pharmaceuticals, Inc., Mylan N.V., Aurobindo Pharma, Pfizer, Inc., Astellas Pharma, Inc.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Egypt Ankylosing Spondylitis Drugs Market Analysis

Egypt Ankylosing Spondylitis Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Ankylosing spondylitis is a kind of arthritis that affects connective tissues. The sacroiliac joints, which connect the spine to the pelvis, become inflamed, but in extreme situations, the spine's bones might fuse together and become very inflexible. A rough estimate of 1.1 Mn Americans, or one out of every 200 adults, are impacted. Abbvie, Amgen, Eli Lilly, Janssen, Merck, Pfizer, Novartis, UCB, and many other leading companies are active in the ankylosing spondylitis global market. To increase their market share, these businesses engage in strategic alliances and acquisitions in addition to concentrating on research and development to bring novel therapies to market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

US Hereditary Angioedema Therapeutics Market Analysis

US Hereditary Angioedema Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. A uncommon genetic condition known as hereditary angioedema (HAE) is characterised by recurrent episodes of swelling in different body areas. It is brought on by a lack or malfunction of certain proteins involved in controlling the immune response. The regulatory authorities have designated numerous HAE therapies as orphan drugs as a result of this classification, pharmaceutical companies are given some incentives including financial advantages and prolonged exclusivity, which may promote investment in HAE R&D. The increasing prevalence and diagnosis of HAE around the world have been driving the growth of the global market for HAE therapies. This trend offers pharmaceutical businesses the chance to increase their market share, make research and development investments, and introduce novel treatments to various geographic areas. Hereditary angioedema therapies are being developed and produced by a number of international pharmaceutical companies (HAE). Takeda Pharmaceutical Company Limited, Inc., CSL Behring, Pharming Group NV, Ionis Pharmaceuticals, Pharvaris, Dyax Corp., Shire (now a part of Takeda), Attune Pharmaceuticals, Prometic Life Sciences Inc., KalVista Pharmaceuticals, and Biocryst are some of these organisations.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

UK Primary Hyperoxaluria (PH) Therapeutics Market Analysis

UK Primary Hyperoxaluria (PH) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. One of the key factors propelling the growth of the hyperoxaluria drug market is the rise in the number of persons with the condition worldwide. The regulatory body's extension of special designations and rising consumer demand for medications including thiazide diuretics, calcium oxalate urinary inhibitors, and others to address a variety of health issues both contribute to the market's quick growth. Major global players in Primary Hyperoxaluria (PH) Therapeutics Market are Allena Pharmaceuticals, Inc., Intellia Therapeutics, Inc., OxThera, Dicerna Pharmaceuticals, Inc, Alnylam Pharmaceuticals, Inc., Pfizer Inc., and Sanofi.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

France Freidreich's Ataxia Market Analysis

France Freidreich?s Ataxia market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Freidreich?s Ataxia is growing rapidly as a result of increase in research and developmental activities for diagnosis and treatment of freidreich?s ataxia, collaborations between academic institutions and industry partners and incentives provided in orphan drug designation by regulatory authorities. PTC Therapeutics, Design Therapeutics, Aurobindo Pharma Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Larimar Therapeutics, Inc., Jupiter Neurosciences, Inc., Lexeo Therapeutics, Zydus Lifesciences Ltd., Cipla Limited, GlaxoSmithKline Plc., Reata Pharmaceuticals, Inc., and Retrotope Inc. are the key global market players operating in global freidreich?s Ataxia Market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Spain Sickle Cell Disease Drugs Market Analysis

Spain Sickle cell disease Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Sickle cell disease Drugs is growing rapidly as a result of increasing prevalence of sickle cell disease , increasing investment for healthcare infrastructure, increase in the number of research and development activities, Support provided by governments of different countries, patient advocacy programmes and incentives provided by regulatory authorities. Global Blood Therapeutics, Novartis, Emmaus Life Sciences, Bluebird Bio, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Mylan N.V., Merck & Co., Inc., Johnson & Johnson Private Limited, Bristol-Myers Squibb Company, AbbVie Inc are the key global market players operating in sickle cell disease Drugs market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Japan Fanconi Anemia (FA) Therapeutics Market Analysis

Japan Fanconi Anemia (FA) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. Aplastic anaemia and hematologic malignancies both have Fanconi anaemia as one of their most common hereditary causes. Fanconi Anemia (FA) Therapeutics Market is driven by lack of numerous competitors, limited therapeutic options, and rising illness cases. Some of the major participants in the global Fanconi Anemia (FA) Therapeutics Market include Foresee Pharmaceuticals, Jasper Therapeutics, Rocket Pharmaceuticals, Elixirgen, Genethon, and Spotlight Therapeutics.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Brazil Myelodysplastic Syndrome (MDS) Therapeutics Market Analysis

Brazil Myelodysplastic Syndrome (MDS) therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The market for pharmaceuticals for myelodysplastic syndrome (MDS) is growing as a result of a number of factors, including a rise in pediatric population, improved awareness, the launch of novel drugs, government initiatives to provide target-specific therapy, and favourable reimbursement policies. Major global players in this market are Abbott, Boehringer Ingelheim International GmbH, Johnson & Johnson Private Limited, MEI Pharma Inc., MTW Endoskopie Manufaktur, Aprea Therapeutics, Dr. Reddy's Laboratories Ltd, AbbVie Inc., Acceleron Pharma, Inc., Mylan N.V., Bristol-Myers Squibb Company, Eisai Co., Ltd., and LGM Pharma are a few other companies that are involved in the pharmaceutical industry.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Egypt Autoimmune Hemolytic Anemia Drugs Market Analysis

Egypt Autoimmune Hemolytic Anemia Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. A rise in the prevalence of certain autoimmune illnesses and malignancies, as well as increased funding for research into innovative interventions and growing demand for novel therapies, are all contributing to an increase in the market for medications to treat autoimmune hemolytic anaemia. Major global players in Autoimmune Hemolytic Anemia Drugs Market are F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd, Zydus Cadila, Vertice Pharma, Concord Biotech, Alkem Labs, Dr. Reddy's Laboratories Ltd, Jubilant Life Sciences Ltd, Strides Pharma Science Limited, Mylan N.V., Novartis AG, Sanofi, Rigel Pharmaceuticals Inc, Incyte Corporation, Alexion Pharmaceuticals, Apellis Pharmaceuticals.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

US Herpes Simplex Virus Therapeutics Market Analysis

US Herpes Simplex Virus Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. Herpes simplex virus (HSV) is a common viral infection that can cause a range of diseases in humans. High Prevalence of HSV Infections, Increasing Awareness and Diagnosis, Continued research and development efforts, Technological advancements and Increasing healthcare expenditure, particularly in developed countries, provides a supportive environment for the growth of the HSV Therapeutics market. Social stigma surrounding herpes, Drug-resistant HSV strains provided by limited treatment options are restraining factors in herpes simplex therapeutics market. GlaxoSmithKline plc, Merck & Co., Inc., Pfizer Inc., Novartis AG, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd. Are global key players in herpes simplex therapeutics market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

UK Prurigo Nodularis Therapeutics Market Analysis

UK Prurigo Nodularis Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Growing research and development activities by key companies and rising government funding in developed areas would be the main drivers of the market demand for prurigo nodularis treatments. Major global players in Prurigo Nodularis Therapeutics Market are Novartis AG (Switzerland), AstraZeneca (UK), Merck & Co., Inc. (US), Sumitomo Corporation (Japan), Allergan (Ireland), LEO Pharma A/S (Denmark), Cipla Inc. (US), Eli Lilly and Company (US), Bayer AG (Germany), Abbott (US), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Johnson & Johnson Private Limited (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sun Pharmaceutical Industries Ltd. (Mumbai), Aurobindo Pharma (Hyderabad), Lupin (Mumbai), Bausch Health Companies Inc. (Canada), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US)

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

France Gaucher Disease Drugs Market Analysis

France Gaucher disease drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for gaucher disease drugs is growing rapidly as a result of rising incidence and prevalence of gaucher disease, increasing infrastructure spending for healthcare, rising acceptance rate of early diagnosis, increasing number of government initiatives to raise awareness and an increasing number of approved therapies for the treatment of Gaucher disease. Aptalis Pharma, Abbott Laboratories, Genzyme Corporation, Pfizer Inc., GlaxoSmithKline (GSK), Eli Lilly and Company, AVROBIO, Shire Human Genetic Therapies, Inc., Anthera Pharmaceuticals, Inc., Enobia Pharma Inc., BioMarin Pharmaceutical Inc., Merck Serono, Zymenex A/S, and MedPro Rx are the top key players of gaucher disease drugs market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Spain Soft Tissue Sarcoma Market Analysis

Spain Soft Tissue Sarcoma market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Soft Tissue Sarcoma is growing rapidly as a result of increasing prevalence and incidence of soft tissue sarcoma, rising awareness about the disease, rising research and development activities on drugs and other therapies, increase in partnerships between pharmaceutical companies for drug development and advancements in diagnostics. Pfizer Inc, Eli Lilly and Company, Johnson & Johnson, Bayer AG, Eisai Co., Ltd., Epizyme, Inc., Adaptimmune Therapeutics, Mylan N.V., Sanofi are the key market players operating in global Soft Tissue Sarcoma market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Japan Fibrodysplasia Ossificans Progressiva (FOP) Therapeutics Market Analysis

Japan Fibrodysplasia Ossificans Progressiva Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. An estimated 1.36 per Mn persons are believed to have the ultra-rare condition fibrodysplasia osseous progressiva, which affects about 900 people worldwide. The market for Fibrodysplasia Ossificans Progressiva Drugs is expanding as a result of growing incidence and prevalence of fibrodysplasia ossificans progressiva, increase in the number of R&D activities, increase in Partnerships and Collaborations between market players. Pfizer Inc., AstraZeneca, Limited, Regeneron Pharmaceuticals, Inc, Clementia Pharmaceuticals, Novartis are the top key market players operating in the global Fibrodysplasia Ossificans Progressiva Therapeutics Market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Brazil Myeloproliferative Disorders (MPD) Therapeutics Market Analysis

Brazil Myeloproliferative Disorders (MPD) therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The market for drugs to treat myeloproliferative disorders is expected to expand as a result of the rising prevalence of the different myeloproliferative disorders, the existence of promising pipeline products, regular product approvals, and rising R&D expenditures on the creation of new drugs for the MPD Treatment market. Major global players in this market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Mylan N.V, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd, Bristol Myers Squibb Company, GSK Plc, Bayer AG, Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim International Gmbh, Sanofi.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Egypt CDKL5 deficiency disorder (CDD) market Analysis

Egypt CDKL5 deficiency disorder Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for CDKL5 deficiency disorder is expanding as a result of increase in global prevalence of CDKL5 deficiency disorder and increase in awareness about neurological diseases. In addition, high expenditure on healthcare and genetic testing, growing demand for targeted therapies, increase in R&D spending for the discovery of novel pharmaceuticals are other reasons . This demand is fueling the development of better pharmaceuticals and other treatment methods for the accurate treatment of CDKL5 deficiency disorder. Some of the key players in the global CDKL5 deficiency disorder market include Marinus pharmaceuticals, REGENXBIO, Zogenix, PTC therapeutics and Ovid therapeutics/ Takeda

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

US Hodgkin Lymphoma Therapeutics Market Analysis

US Hodgkin Lymphoma Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. Hodgkin lymphoma is a type of cancer that originates from white blood cells called lymphocytes. Increasing incidence of Hodgkin lymphoma, Extensive research and development activities, Growing adoption of immunotherapies, Improved reimbursement policies and increased insurance coverage for cancer treatments along with growing awareness are drivers for Hodgkin Lymphoma Therapeutics Market. Bristol Myers Squibb, Merck & Co., Inc. (MSD), Takeda Pharmaceutical Company Limited, Roche Holding AG, Novartis AG, Pfizer Inc., AstraZeneca plc, Johnson & Johnson, AbbVie Inc., Celgene Corporation (a subsidiary of Bristol Myers Squibb), Amgen Inc., Gilead Sciences, Inc. are the global companies in Hodgkin lymphoma therapeutics market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

UK Pseudomonas Aeruginosa Infection Therapeutics Market Analysis

UK Pseudomonas Aeruginosa Infection Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Industry income is expected to increase as a result of increased pseudomonas aeruginosa infections, an ageing population, future innovative antibiotic formulations, an increase in patients, and greater public awareness of the infection. Major global players in Pseudomonas Aeruginosa Infection Therapeutics Market are Allergan, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Lupin Pharmaceuticals, Inc., AstraZeneca, Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc, Merck & Co.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

France Guillain-Barre Syndrome (GBS) Drugs Market Analysis

France Guillain-Barre Syndrome (GBS) drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Guillain-Barre Syndrome (GBS) drugs is growing rapidly as a result of increase in the incidence and prevalence of the guillain-barre syndrome, advancements in technology and development in healthcare, support and funding by governments globally, rise in the geriatric population and increase in the prevalence of chikungunya and immune diseases like multiple sclerosis , increase in the approvals of immunoglobulins by regulatory bodies and increase in research and development activities by pharmaceutical companies. Alexion Pharmaceuticals Inc., Annexon Inc., Cellenkos Inc., Cresence AS, Akari Therapeutics Plc, Chugai Pharmaceutical Co Ltd are the key market players operating in global gullian barre syndrome drugs market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Spain Wilson's Disease Drugs Market Analysis

Spain Wilson?s Disease Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Wilson?s Disease Drugs is growing rapidly as a result of rising prevalence of the disease, advancements in diagnostic techniques , increase in awareness about the disease due to patient advocacy programmes , support and incentives from regulatory authorities like incentives and orphan drug designations and increasing investment in research and development activities. Amneal Pharmaceuticals, Meda Pharmaceuticals, Teva Pharmaceuticals Industries Ltd. , Taj Pharmaceutical Limited, Ipsen Pharma, TSUMURA & CO., Mylan pharmaceuticals are the key global market players in wilson?s disease drugs market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Japan Fragile-X Syndrome Therapeutics Market Analysis

Japan Fragile-X Syndrome Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The most typical cause of inherited learning disabilities is fragile X syndrome (FXS), an X-linked genetic disorder. The global market is driven by the higher prevalence of males than females, the transmission of the disease from one generation to the next, and the rise in patients suffering from this and other genetic disorders. Aelis Farma Sas, Alcobra Ltd, Amo Pharma Limited, Confluence Pharmaceuticals Llc, F. Hoffmann-la Roche Ltd., Marinus Pharmaceuticals, Mi.to. Technology S.r.l., Neuren Pharmaceuticals Limited, Ovid Therapeutics Inc., Sage Therapeutics, Acadia Pharmaceuticals, Advanz Pharma Corp, Boehringer Ingelheim, GlaxoSmithKline, H. Lundbeck, Janssen, Novartis, Ots.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

Rare Diseases

Brazil Narcolepsy Therapeutics Market Analysis

Brazil narcolepsy therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The increased prevalence of narcoleptic disorders worldwide, rising stress levels, an ageing population, and growing public awareness of the variety of treatments for this condition are all predicted to have a positive impact on the market. Major global players in Narcolepsy Therapeutics Market are Avadel Pharmaceuticals Inc, Harmony Biosciences (BIOPROJET), Jazz Pharmaceuticals PLC, Ligand Pharmaceuticals Incorporated, Novartis, Shionogi Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceuticals USA Inc.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: Jul, 2023 | PRICE: $3999

subscribe to our newsletter
up